• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Oceania & ASSEAN - Articles and news items


Santhera’s Duchenne muscular dystrophy treatment receives Australian orphan drug designation

Industry news / 13 September 2016 / Niamh Louise Marriott, Digital Content Producer

The Australian Therapeutic Goods Administration (TGA) has granted orphan drug designation to Santhera Pharmaceutical’s idebenone (raxone) for the treatment of Duchenne muscular dystrophy (DMD). The product has already received ODD from European, Swiss and US authorities…


Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +